Locally Advanced Proximal Gastric or Gastroesophageal Junction AdenocarcinomaPOSITNCT07674342
Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma
A study testing Short-course Radiotherapy and Neoadjuvant Serplulimab and SOX Chemotherapy in people with Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma, run by Tongji Hospital at 1 site in China.
Trial summary
This study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal junction. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma
- What is being tested?
- Short-course Radiotherapy and Neoadjuvant Serplulimab and SOX Chemotherapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 146 participants
- Where
- 1 siteChina
- Study dates
- 30 Jun 2026to 30 Jun 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The participant voluntarily joins this study, is able to complete the signing of the informed consent form, and demonstrates good compliance.
- Age 18-75 years (at the time of signing the informed consent), regardless of gender.
- Adenocarcinoma confirmed by histology and/or cytology, diagnosed as locally advanced according to the AJCC 8th edition criteria, with cTNM staged as cT3-4 or N+ M0 based on endoscopic ultrasound or contrast-enhanced CT/MRI, and the patient agrees to receive neoadjuvant therapy; the lesion is assessed by the investigator as resectable or potentially resectable; after MDT evaluation, radical resection is planned with standard D2 lymph node dissection.
- Primary lesion site restrictions: (1) Adenocarcinoma of the gastroesophageal junction: Siewert type II-III; (2) Upper stomach cancer: the lower edge of the tumor is located within the upper third of the stomach, mainly involving the cardia, fundus, or upper part of the stomach body.
- Has not previously received systemic treatment for the current disease, including anti-tumor radiotherapy/chemotherapy or immunotherapy.
- ECOG score 0-1.
Show all 11Show fewer
- Estimated survival period >= 6 months.
- Preoperative chest, abdominal, and pelvic CT, as well as FAPI PET or PET-CT, to rule out distant metastasis.
- Major organ function is satisfactory and meets the following criteria: (1) Complete blood count (without blood transfusion or use of hematopoietic growth factors within 14 days to correct status): hemoglobin (Hb) >=90 g/L; absolute neutrophil count (ANC) >=1.5 × 10^9/L; platelets (PLT) >=80 × 10^9/L; (2) Biochemical tests: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5 × ULN; total bilirubin (TBIL) <=1.5 × ULN; serum creatinine (Cr) <=1.5 × ULN, or creatinine clearance >=60 mL/min; (3) Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) <=1.5 × ULN; (4) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) >=50%.
- The doctor clinically determines that there is sufficient organ function.
- Subjects of reproductive potential must use appropriate contraception during the study and for 120 days after the study ends, have a negative serum pregnancy test within 7 days prior to study enrollment, and must not be breastfeeding.
Who cannot join
- Undergo radiotherapy within 4 weeks before enrollment, or radionuclide therapy within 8 weeks.
- Within 6 months before enrollment: esophageal or gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, fistulas, intestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding.
- Diagnosis of malignancies other than gastric cancer within 5 years prior to first administration (excluding completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or completely resected carcinoma in situ).
- Presence of distant metastasis (M1), including but not limited to: peritoneal metastasis (confirmed by imaging or laparoscopy), ascites or positive peritoneal lavage cytology, metastasis to organs such as liver, lung, or bone; cases where imaging suggests metastasis to para-aortic lymph nodes (No.16).
- Imaging suggests excessive regional lymph node burden: suspicious/positive lymph node involvement in >=3 anatomical stations; or multiple lymph nodes are fused/form a cluster (matted nodes); or any lymph node has a short axis >=15 mm.
- The tumor lesion has a serious tendency to bleed (such as the presence of an active deep large ulcer, a history of vomiting blood or black stools within 2 months before signing the informed consent, or a risk of major gastrointestinal bleeding as determined by the investigator), or has received blood transfusion treatment within 4 weeks prior to the study medication.
Show all 23Show fewer
- Inability to swallow oral medications, malabsorption syndrome, or other conditions affecting gastrointestinal absorption.
- Currently participating in interventional clinical research treatment, or has received other investigational drugs or used investigational devices within 4 weeks prior to the first administration.
- Previously received systemic or local anti-tumor treatment for gastric cancer, including curative surgery, chemotherapy, radiotherapy, immunotherapy (such as immune checkpoint inhibitors, agonists, or cell therapy), biological agents, or small molecule targeted drugs.
- Systemic therapy with traditional Chinese medicine having anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, interleukins, except for local use to control pleural effusion) within 2 weeks prior to the first dose.
- Active autoimmune disease that required systemic treatment (such as disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years before the first administration. Replacement therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered systemic treatment.
- The participant is receiving systemic corticosteroid therapy (excluding nasal, inhaled, or other forms of topical corticosteroids) or any other form of immunosuppressive therapy within the 7 days prior to the first study drug administration; Note: The use of physiological doses of corticosteroids (<=10 mg/day of prednisone or equivalent) is allowed; short courses of corticosteroids are allowed for medically necessary reasons such as chemotherapy-induced nausea, premedication for contrast agent allergy, or other short-term medical needs.
- Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
- Known allergies to medications used in this study.
- Peripheral neuropathy >= grade 2.
- Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive).
- Subjects with active hepatitis B or hepatitis C (HBsAg positive with HBV DNA levels above the upper limit of normal; HCVAb positive with HCV RNA levels above the upper limit of normal (Note: Subjects who are HBV DNA positive may be enrolled if they are willing to undergo full antiviral treatment throughout the study and have already started treatment before enrollment, subject to consultation with an infectious disease specialist).
- Within 30 days before the first dose (Cycle 1, Day 1), live vaccines were administered; inactivated influenza vaccines for injection against seasonal flu are allowed within 30 days before the first dose; however, intranasal live attenuated influenza vaccines are not allowed.
- Pregnant or breastfeeding women.
- Presence of any severe or uncontrollable systemic disease, such as: (1) Significant and symptomatic abnormalities on resting electrocardiogram in rhythm, conduction, or morphology that are difficult to control, such as complete left bundle branch block, second-degree or higher heart conduction block, ventricular arrhythmias, or atrial fibrillation; (2) Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) class >= 2; (3) Any arterial thrombosis, embolism, or ischemia within 6 months prior to treatment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack; (4) Long-term poorly controlled hypertension (systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg); (5) History of non-infectious pneumonia requiring corticosteroid therapy within 1 year before initial dosing, or currently active interstitial lung disease; (6) Significant bleeding disorders or a history of coagulopathy; current or past long-term anticoagulant therapy (e.g., atrial fibrillation with CHADS2 score >=2); (7) Active pulmonary tuberculosis; (8) History of inflammatory bowel disease (such as Crohn's disease, ulcerative colitis) or chronic diarrhea; (9) Major surgery or major trauma within 30 days prior to treatment; minor local surgery within 3 days prior to treatment (excluding central venous catheter placement via peripheral vein); (10) Presence of active or uncontrolled infection requiring systemic therapy; (11) Presence of clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction; (12) Uncontrolled comorbidities including but not limited to decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer or gastritis, or mental/social conditions that interfere with protocol compliance or informed consent; (13) Poorly controlled diabetes (fasting blood glucose (FBG) >10 mmol/L); (14) Urinalysis indicating proteinuria >=++, confirmed by 24-hour urine protein quantification >1.0 g.
- Known history of mental illness, substance abuse, alcoholism, or drug addiction.
- Any history or evidence of disease that may interfere with the trial results, hinder the subject's full participation in the study, abnormal treatment or laboratory test results, or any other condition that the investigator considers unsuitable for enrollment. The investigator believes that there are other potential risks making the subject unsuitable to participate in this study.
- Local or systemic diseases caused by tumors, or tumor-related complications with high medical risk or uncertain prognosis (for example, leukocyte response resulting in leukocytes >20 × 10^9/L, cachexia, weight loss >10% in the three months before screening), or BMI <=18).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430030
Tongji Hospital, Huazhong University of Science and Technology, +86-027-83662640, ims@tjh.tjmu.edu.cn
About this study
Official title: A Prospective, Multicenter, Randomized Controlled Study of Neoadjuvant PD-1 Inhibitor Combined With SOX Chemotherapy With or Without Short-Course Radiotherapy (With Omission of Regional Lymph Node Irradiation) for Locally Advanced Upper Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal junction. After providing informed consent and meeting the eligibility criteria, enrolled patients will be randomized into two cohorts: Cohort 1 (experimental group) will receive sequential short-course radiotherapy (SCRT) followed by four cycles of SOX plus serplulimab as neoadjuvant therapy prior to surgery; Cohort 2 (control group) will receive four cycles of SOX plus serplulimab as neoadjuvant therapy before surgery. Postoperatively, all patients will continue with four cycles of SOX plus serplulimab as adjuvant therapy, with serplulimab maintained for one year. If patients do not meet the criteria for radical gastrectomy, alternative conservative treatments or surgical approaches will be considered following multidisciplinary team (MDT) discussion. The study aims to evaluate the efficacy and safety of SOX combined with serplulimab, and sequential SCRT followed by SOX plus serplulimab as neoadjuvant therapy leading to radical resection of gastric cancer. All enrolled patients will undergo PD-L1 expression analysis (CPS and TPS scores) and microsatellite instability status (MSI-H population). Where tissue availability and research center conditions permit, exploratory assessments will include minimal residual disease (MRD) measured at baseline, after neoadjuvant therapy, post-surgery, and after adjuvant therapy, tumor mutational burden (TMB), and whole-exome sequencing of tumor tissue. Radiological evaluations will be conducted every 3 months ± 1 week for the first 2 years post-surgery, then every 6 months ± 2 weeks up to 5 years, and annually thereafter until disease recurrence. Survival follow-up will occur every three months after recurrence. Safety visits will span from the first dose to 30 days after the last dose or initiation of new antitumor therapy.
- Being tested
- Short-course Radiotherapy, Neoadjuvant Serplulimab and SOX Chemotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Short-course RadiotherapyRadiation
Exemption from short-course radiotherapy for lymph nodes (5 sessions)
Neoadjuvant Serplulimab and SOX ChemotherapyDrug
4-week regimen of SOX combined with Sutelizumab
| Study group | Role | What they receive |
|---|---|---|
| Neoadjuvant Serplulimab and SOX Chemotherapy with Lymph Node-Sparing Short-Course Radiotherapy | Experimental | Neoadjuvant Serplulimab and SOX Chemotherapy with Lymph Node-Sparing Short-Course Radiotherapy Receives: Radiation: Short-course Radiotherapy; Drug: Neoadjuvant Serplulimab and SOX Chemotherapy |
| Neoadjuvant Serplulimab and SOX Chemotherapy | Active comparator | Neoadjuvant Serplulimab and SOX Chemotherapy Receives: Drug: Neoadjuvant Serplulimab and SOX Chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological Complete Response, pCR
pCR refers to the situation where, after patients undergo neoadjuvant therapy (such as chemotherapy, targeted therapy or immunotherapy), the tumor tissues and lymph nodes removed through surgery show no detectable surviving cancer cells upon pathological examination.
Measured: Up to 2 weeks after surgery。
Secondary outcomes (7)
R0 resection rate
The R0 resection rate is a professional term in tumor surgery, referring to the proportion of surgeries where the tumor is completely removed under a microscope and there are no cancer cells remaining at the surgical margin.
Measured: Up to 2 weeks after surgery。
Incidence of adverse reactions
Measured: From the first dose of study drug up to 30 days after the last dose
3-year event-free survival
Measured: 3 years after the start of treatment
Major Pathological Response, MPR
Major Pathological Response (MPR) is defined as the proportion of patients with ≤ 10% viable tumor cells in the surgically resected specimen after neoadjuvant therapy.
Measured: Perioperative period
Quality of Life (QoL)
Measured: At baseline and every 6 weeks during treatment until surgery
3-year disease-free survival
Measured: 3 years after the start of treatment
Overall survival
Measured: Up to 3 years from randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2026
- Study start30 Jun 2026 (estimated)
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Locally Advanced Proximal Gastric or Gastroesophageal Junction AdenocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 146 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tongji Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07674342
- Sponsor's protocol ID
- TJ-IRB202603015
- Other IDs
- 2024ZD0520604
- Acronym
- POSIT
- Status last verified
- Jun 2026
- First submitted
- 16 Jun 2026
- Last updated
- 29 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicenter, Randomized Controlled Study of Neoadjuvant PD-1 Inhibitor Combined With SOX Chemotherapy With or Without Short-Course Radiotherapy (With Omission of Regional Lymph Node Irradiation) for Locally Advanced Upper Gastric or Gastroesophageal Junction Adenocarcinoma
- ClinicalTrials.gov ID
- NCT07674342
- Acronym / sponsor ID
- POSIT / TJ-IRB202603015
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 146 participants (estimated)
- Lead sponsor
- Tongji HospitalUniversity, hospital or other
- Study start
- 30 Jun 2026 (estimated)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2031 (estimated)
- First posted
- 29 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal junction. After providing informed consent and meeting the eligibility criteria, enrolled patients will be randomized into two cohorts: Cohort 1 (experimental group) will receive sequential short-course radiotherapy (SCRT) followed by four cycles of SOX plus serplulimab as neoadjuvant therapy prior to surgery; Cohort 2 (control group) will receive four cycles of SOX plus serplulimab as neoadjuvant therapy before surgery. Postoperatively, all patients will continue with four cycles of SOX plus serplulimab as adjuvant therapy, with serplulimab maintained for one year. If patients do not meet the criteria for radical gastrectomy, alternative conservative treatments or surgical approaches will be considered following multidisciplinary team (MDT) discussion. The study aims to evaluate the efficacy and safety of SOX combined with serplulimab, and sequential SCRT followed by SOX plus serplulimab as neoadjuvant therapy leading to radical resection of gastric cancer. All enrolled patients will undergo PD-L1 expression analysis (CPS and TPS scores) and microsatellite instability status (MSI-H population). Where tissue availability and research center conditions permit, exploratory assessments will include minimal residual disease (MRD) measured at baseline, after neoadjuvant therapy, post-surgery, and after adjuvant therapy, tumor mutational burden (TMB), and whole-exome sequencing of tumor tissue. Radiological evaluations will be conducted every 3 months ± 1 week for the first 2 years post-surgery, then every 6 months ± 2 weeks up to 5 years, and annually thereafter until disease recurrence. Survival follow-up will occur every three months after recurrence. Safety visits will span from the first dose to 30 days after the last dose or initiation of new antitumor therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Neoadjuvant Serplulimab and SOX Chemotherapy with Lymph Node-Sparing Short-Course Radiotherapy | Experimental | Radiation: Short-course Radiotherapy, Drug: Neoadjuvant Serplulimab and SOX ChemotherapyNeoadjuvant Serplulimab and SOX Chemotherapy with Lymph Node-Sparing Short-Course Radiotherapy |
| Neoadjuvant Serplulimab and SOX Chemotherapy | Active comparator | Drug: Neoadjuvant Serplulimab and SOX ChemotherapyNeoadjuvant Serplulimab and SOX Chemotherapy |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- The participant voluntarily joins this study, is able to complete the signing of the informed consent form, and demonstrates good compliance.
- Age 18-75 years (at the time of signing the informed consent), regardless of gender.
- Adenocarcinoma confirmed by histology and/or cytology, diagnosed as locally advanced according to the AJCC 8th edition criteria, with cTNM staged as cT3-4 or N+ M0 based on endoscopic ultrasound or contrast-enhanced CT/MRI, and the patient agrees to receive neoadjuvant therapy; the lesion is assessed by the investigator as resectable or potentially resectable; after MDT evaluation, radical resection is planned with standard D2 lymph node dissection.
- Primary lesion site restrictions: (1) Adenocarcinoma of the gastroesophageal junction: Siewert type II-III; (2) Upper stomach cancer: the lower edge of the tumor is located within the upper third of the stomach, mainly involving the cardia, fundus, or upper part of the stomach body.
- Has not previously received systemic treatment for the current disease, including anti-tumor radiotherapy/chemotherapy or immunotherapy.
Key exclusion criteria (23 listed)
- Undergo radiotherapy within 4 weeks before enrollment, or radionuclide therapy within 8 weeks.
- Within 6 months before enrollment: esophageal or gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, fistulas, intestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding.
- Diagnosis of malignancies other than gastric cancer within 5 years prior to first administration (excluding completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or completely resected carcinoma in situ).
- Presence of distant metastasis (M1), including but not limited to: peritoneal metastasis (confirmed by imaging or laparoscopy), ascites or positive peritoneal lavage cytology, metastasis to organs such as liver, lung, or bone; cases where imaging suggests metastasis to para-aortic lymph nodes (No.16).
- Imaging suggests excessive regional lymph node burden: suspicious/positive lymph node involvement in >=3 anatomical stations; or multiple lymph nodes are fused/form a cluster (matted nodes); or any lymph node has a short axis >=15 mm.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Short-course RadiotherapyExemption from short-course radiotherapy for lymph nodes (5 sessions) | Radiation | Neoadjuvant Serplulimab and SOX Chemotherapy with Lymph Node-Sparing Short-Course Radiotherapy |
| Neoadjuvant Serplulimab and SOX Chemotherapy4-week regimen of SOX combined with Sutelizumab | Drug | Neoadjuvant Serplulimab and SOX Chemotherapy, Neoadjuvant Serplulimab and SOX Chemotherapy with Lymph Node-Sparing Short-Course Radiotherapy |
Primary outcome
Pathological Complete Response, pCR
Time frame: Up to 2 weeks after surgery。
pCR refers to the situation where, after patients undergo neoadjuvant therapy (such as chemotherapy, targeted therapy or immunotherapy), the tumor tissues and lymph nodes removed through surgery show no detectable surviving cancer cells upon pathological examination.
7 secondary outcomes
R0 resection rate
Time frame: Up to 2 weeks after surgery。
Incidence of adverse reactions
Time frame: From the first dose of study drug up to 30 days after the last dose
3-year event-free survival
Time frame: 3 years after the start of treatment
Major Pathological Response, MPR
Time frame: Perioperative period
Quality of Life (QoL)
Time frame: At baseline and every 6 weeks during treatment until surgery
3-year disease-free survival
Time frame: 3 years after the start of treatment
Overall survival
Time frame: Up to 3 years from randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Individual participant dataSharing planned: Yes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Short-course Radiotherapy and Neoadjuvant Serplulimab and SOX Chemotherapy in people with Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma, run by Tongji Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Junbo Hu (+86-027-83665215, jbhu@tjh.tjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological Complete Response, pCR (time frame: Up to 2 weeks after surgery。). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.